Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade

@article{1673998,
   author = {Lakomý, Radek and Kazda, Tomáš and Selingerová, Iveta and Poprach, Alexandr and Pospíšil, Petr and Belanová, Renata and Fadrus, Pavel and Vybíhal, Václav and Smrčka, Martin and Jančálek, Radim and Hynková, Ludmila and Múčková, Katarína and Hendrych, Michal and Šána, Jiří and Slabý, Ondřej and Šlampa, Pavel},
   article_location = {Lausanne},
   article_number = {July 2020},
   doi = {http://dx.doi.org/10.3389/fonc.2020.00840},
   keywords = {glioblastoma; chemotherapy; radiotherapy; rapid early progression; overall survival; real-world evidence},
   language = {eng},
   issn = {2234-943X},
   journal = {Frontiers in Oncology},
   title = {Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade},
   url = {https://www.frontiersin.org/articles/10.3389/fonc.2020.00840/full},
   volume = {10},
   year = {2020}
}

TY  - JOUR
ID  - 1673998
AU  - Lakomý, Radek - Kazda, Tomáš - Selingerová, Iveta - Poprach, Alexandr - Pospíšil, Petr - Belanová, Renata - Fadrus, Pavel - Vybíhal, Václav - Smrčka, Martin - Jančálek, Radim - Hynková, Ludmila - Múčková, Katarína - Hendrych, Michal - Šána, Jiří - Slabý, Ondřej - Šlampa, Pavel
PY  - 2020
TI  - Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade
JF  - Frontiers in Oncology
VL  - 10
IS  - July 2020
SP  - 1-11
EP  - 1-11
PB  - Frontiers Media S.A.
SN  - 2234943X
KW  - glioblastoma
KW  - chemotherapy
KW  - radiotherapy
KW  - rapid early progression
KW  - overall survival
KW  - real-world evidence
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2020.00840/full
L2  - https://www.frontiersin.org/articles/10.3389/fonc.2020.00840/full
N2  - The aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblastoma irradiated from 1/2014 to 12/2017 in our cancer center was compared with an already published historical control of patients treated in 1/2003-12/2009. A total of new 155 patients was analyzed, median age 60.9 years, 61% men, 58 patients (37%) underwent gross total tumor resection. Stupp's regimen was indicated in 90 patients (58%), 65 patients (42%) underwent radiotherapy alone. Median progression-free survival in Stupp's regimen cohort was 6.7 months, median OS 16.0 months, and 2-year OS 30.7%. OS was longer if patients were able to finish at least three cycles of adjuvant chemotherapy (median 23.3 months and 43.9% of patients lived at 2 years after surgery). Rapid early progression prior to radiotherapy was a negative prognostic factor with HR 1.87 (p= 0.007). The interval between surgery and the start of radiotherapy (median 6.7 weeks) was not prognostically significant (p= 0.825). The median OS in the current cohort was about 2 months longer than in the historical control group treated 10 years ago (16 vs. 13.8 months) using the same Stupp's regimen. Taking into account differences in patient's characteristics between current and historical cohorts, age, extent of resection, and ECOG patient performance status adjusted HR (Stupp's regimen vs. RT alone) for OS was determined as 0.45 (p= 0.002).
ER  - 

LAKOMÝ, Radek, Tomáš KAZDA, Iveta SELINGEROVÁ, Alexandr POPRACH, Petr POSPÍŠIL, Renata BELANOVÁ, Pavel FADRUS, Václav VYBÍHAL, Martin SMRČKA, Radim JANČÁLEK, Ludmila HYNKOVÁ, Katarína MÚČKOVÁ, Michal HENDRYCH, Jiří ŠÁNA, Ondřej SLABÝ and Pavel ŠLAMPA. Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade. \textit{Frontiers in Oncology}. Lausanne: Frontiers Media S.A., 2020, vol.~10, July 2020, p.~1-11. ISSN~2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2020.00840.